Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.64 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4695209 | 0.86 | PPARG (0.69) | PPARGCYP3A4PTGDR2 | |
| SCHEMBL4696073 | 0.85 | PPARG (0.69) | PPARGCYP3A4PTGDR2 | |
| SCHEMBL4696090 | 0.83 | PPARG (1.00) | PPARGCYP3A4 | |
| SCHEMBL2033527 | 0.81 | PPARG (0.66) | PPARGCYP3A4 | |
| SCHEMBL2029444 | 0.81 | PPARG (0.69) | PPARGCYP3A4 | |
| SCHEMBL12632892 | 0.80 | PPARG (0.60) | PPARGCYP3A4MEN1ALDH1A1KMT2A | |
| SCHEMBL2029374 | 0.80 | PPARG (0.66) | PPARGCYP3A4 | |
| SCHEMBL12584877 | 0.80 | PPARG (0.75) | PPARGCYP3A4 | |
| SCHEMBL2029481 | 0.80 | PPARG (1.00) | PPARGCYP3A4 | |
| SCHEMBL2030863 | 0.80 | PPARG (0.71) | PPARGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1053227-B1 | PPAR-GAMMA MODULATORS | AMGEN INC (US) | 2008-11-05 | — | — | EP | disclosed |
| US-7439242-B2 | PPARγ modulators | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-6620827-B2 | Peroxisome proliferator-activated receptors-gamma to control lipid metabolism ane obesity; antidiabetic, -inflammatory and -arthritic agents; non-insulin dependent diabetes; antilipemic and -cholesterol agents | TULARIK INC. | 2003-09-16 | — | — | US | disclosed |
| US-20030088103-A1 | PPARgamma modulators | TULARIK INC. (US) | 2003-05-08 | — | — | US | disclosed |
| US-20010027200-A1 | PPARgamma modulators | TULARIK INC. | 2001-10-04 | — | — | US | disclosed |
| US-6200995-B1 | PYRIDYLOXYBENZENESULFONAMIDE DERIVATIVES; DIABETES, OBESITY | TULARIK INC. | 2001-03-13 | — | — | US | disclosed |
| EP-1053227-A1 | PPAR-GAMMA MODULATORS | TULARIK, INC. (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999038845-A1 | PPAR-GAMMA MODULATORS | TULARIK INC. (US) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030088103-A1 | PPARgamma modulators | PPARG, PPARA, PPARD | PPARG 1/4885CYP3A4 1290/4885PTGDR2 123/4885 |
| US-20010027200-A1 | PPARgamma modulators | PPARG, PPARA, PPARD | PPARG 1/4885CYP3A4 1290/4885PTGDR2 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.